HBOT for long COVID and sports recovery: what trials show

What kind of recovery has been studied?

HBOT research has not established a general promise of faster recovery. Long COVID trials have produced mixed results, and sports studies are small. Less soreness, improved endurance, healing an injury, and being able to resume everyday activities are different goals. Ask whether the study a clinic cites measured the improvement you want.

The recognized medical use of HBOT for selected traumatic ischemic injuries also does not establish routine benefit after ordinary training or every sports injury. The condition and clinical context are part of the indication. For a recovery service, ask exactly what problem is being treated and whether the cited research assessed that problem. Ask how the clinic will measure progress: a blood test, a symptom rating, a performance test, or your ability to resume activities without worsening symptoms.

The small master-athlete trial

A 2022 blinded randomized trial enrolled 37 healthy master athletes aged 40–50, with 31 included in final analysis. Repeated HBOT was compared with sham, and the study reported improved aerobic capacity measures. Muscle-biopsy analyses explored mitochondrial respiration in an even smaller subset. This is a more informative design than an athlete testimonial, yet its small and selected sample leaves uncertainty about replication and applicability beyond similar participants.

Aerobic test gains are not the same outcome as injury healing, elite competition results, or long-term health. Some participants were not included in the final analysis, and the muscle-cell findings came from a smaller group still. The trial record, NCT03524989, helps identify the original study instead of relying on a commercial summary. The useful next questions concern independent confirmation, duration of benefit, different athletic populations, and whether any benefit justifies the time, cost, and treatment burden.

A youth-football trial did not show objective recovery gains

A 2024 double-blind randomized study included 20 elite youth football players after a match. A single HBOT session was compared with placebo. It found no between-group advantage in measured biochemical or physical-performance outcomes, although a short-term self-reported recovery score favored HBOT. This illustrates why subjective recovery, blood markers, and performance should be reported separately. A positive result on one rating does not mean the overall intervention improved objective recovery.

The trial was small and examined one exposure in one sport. It cannot exclude every possible effect of repeated treatment or answer questions about diagnosed injury. Equally, its narrowness does not permit a claim that match recovery is established. When evidence varies, a useful provider explanation acknowledges which outcomes improved, which did not, and what remains unknown. Famous athletes using a chamber provide information about adoption, not a controlled estimate of benefit.

Long COVID: the encouraging 2022 study

A 2022 sham-controlled trial randomized 79 people with persistent post-COVID symptoms; 73 completed the protocol and were included in the analysis. It reported improvements in cognitive and several symptom domains after a 40-session course, with initial assessment shortly after treatment. These results helped generate interest in the intervention. They remain an important signal, while the modest sample, numerous measured outcomes, and short initial follow-up constrain the certainty and range of conclusions.

The study disclosed commercial relationships involving AVIV Scientific. Such disclosures allow readers to consider incentives; they do not prove the findings false. Publications describing imaging, symptoms, or other physiology from the same trial should be recognized as related analyses rather than counted as independent replications. NCT04647656 identifies the study. A claim that several papers prove the treatment works should first establish how many different groups of participants and independent trial teams are involved.

Two 2025 controlled studies found no advantage

HOT-LoCO randomized 80 adults to 10 HBOT or sham sessions; 79 contributed to the primary analysis. At 13 weeks, it found no significant between-group improvement in its primary physical-function and physical-role domains. Both groups improved. A separate 2025 four-arm trial randomized 101 patients among different pressure and oxygen combinations and also found no significant advantage in symptom, functional, or cognitive outcomes. A consultation should account for these findings as well as the earlier positive trial.

Taken together, these trials do not establish HBOT as a routine long COVID treatment. They tested different courses and populations, so they cannot settle every possible use. A clinic proposing a longer course should explain the evidence for that course and the remaining uncertainty. For HOT-LoCO (NCT04842448), use the completed results rather than an earlier study plan or preliminary report.

Why comparing studies takes care

The positive 2022 trial and the 2025 trials that found no advantage used different treatment courses and measured different outcomes. Participants also differ in disease history, symptom burden, and accompanying care. Those differences generate hypotheses about who might benefit; they do not confirm a subgroup or establish that a longer commercial course will succeed. A provider suggesting a specific distinction should identify a trial designed to test it, instead of treating the explanation as evidence by itself.

Long COVID recovery can vary over time. A personal improvement during a treatment course can therefore be important to the individual while remaining difficult to attribute. Controlled studies ask whether improvement exceeds what occurred with comparison care. They should also assess whether benefit lasts and whether activity tolerance changes meaningfully. Fatigue, cognition, pain, sleep, and physical limitations are different domains; success in one should not be described as a cure for the entire condition.

Costs and treatment burden

For an experimental recovery service, the decision includes uncertainty, travel, time away from work or family, treatment discomfort, and cost. A course described in research is not a personal recommendation to reproduce it. Ask what the provider would count as meaningful improvement, when it will be assessed, and whether the measurement can distinguish expected fluctuation from benefit. A refund promise or a satisfaction statistic cannot substitute for a comparative clinical outcome.

Safety oversight also matters. The FDA has highlighted serious injuries and deaths associated with HBOT devices and emphasizes supervised treatment, training, maintenance, and fire precautions. A small trial cannot reliably establish the absence of rare harms. Research enrollment may have different eligibility, follow-up, and payment arrangements from routine self-pay care. Trial status should be verified directly before making plans, and an advertised research affiliation should identify a specific registered study and responsible research team.

• Request the study for the exact recovery outcome being advertised.
• Distinguish symptom ratings from objective performance and independence.
• Ask whether follow-up includes everyone enrolled, including withdrawals.
• Clarify total cost, oversight, adverse-event reporting, and trial status.

Questions to ask

• Is the goal sports performance, injury healing, or relief of a specific long COVID symptom?
• Does the provider explain the negative 2025 long COVID trials?
• Are claimed publications independent studies or analyses of one cohort?
• What improvement would matter enough to justify the burden of treatment?

Sources